- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-pentamer
- Ligands
- 5 x H92: 4-[5-[(1~{R},2~{R},4~{S})-7-azabicyclo[2.2.1]heptan-2-yl]-2-fluoranyl-pyridin-3-yl]benzamide(Non-covalent)
- 5 x PO4: PHOSPHATE ION(Non-functional Binders)
PO4.2: 7 residues within 4Å:- Chain A: K.42, S.167, E.170, E.210
- Chain B: D.94, R.96
- Ligands: H92.1
6 PLIP interactions:3 interactions with chain B, 3 interactions with chain A- Hydrogen bonds: B:D.94, A:E.170
- Water bridges: B:D.94, A:K.42
- Salt bridges: B:R.96, A:K.42
PO4.13: 7 residues within 4Å:- Chain B: K.42, S.167, E.170, E.210
- Chain C: D.94, R.96
- Ligands: H92.8
5 PLIP interactions:3 interactions with chain B, 2 interactions with chain C- Hydrogen bonds: B:S.167, C:D.94
- Water bridges: B:Y.212
- Salt bridges: B:K.42, C:R.96
PO4.16: 7 residues within 4Å:- Chain C: K.42, S.167, E.170, E.210
- Chain D: D.94, R.96
- Ligands: H92.15
4 PLIP interactions:3 interactions with chain C, 1 interactions with chain D- Hydrogen bonds: C:E.170, C:E.170
- Salt bridges: C:K.42, D:R.96
PO4.22: 7 residues within 4Å:- Chain D: K.42, S.167, E.170, E.210
- Chain E: D.94, R.96
- Ligands: H92.21
3 PLIP interactions:2 interactions with chain D, 1 interactions with chain E- Hydrogen bonds: D:E.210
- Salt bridges: D:K.42, E:R.96
PO4.30: 7 residues within 4Å:- Chain A: D.94, R.96
- Chain E: K.42, S.167, E.170, E.210
- Ligands: H92.29
6 PLIP interactions:3 interactions with chain A, 3 interactions with chain E- Hydrogen bonds: A:D.94, E:E.170
- Water bridges: A:D.94, E:K.42
- Salt bridges: A:R.96, E:K.42
- 20 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 6 residues within 4Å:- Chain A: D.68, R.114, Q.117, R.139, S.141
- Chain E: R.114
Ligand excluded by PLIPEDO.4: 6 residues within 4Å:- Chain A: Q.55, S.184, Y.186
- Chain E: Y.110, S.111, M.143
Ligand excluded by PLIPEDO.5: 5 residues within 4Å:- Chain A: P.38, W.103, Y.166
- Chain B: R.96, I.123
Ligand excluded by PLIPEDO.7: 8 residues within 4Å:- Chain A: A.109, Y.110, S.111, S.112, M.143
- Chain B: Q.55, V.70, L.119
Ligand excluded by PLIPEDO.9: 6 residues within 4Å:- Chain A: R.114
- Chain B: D.68, R.114, Q.117, R.139, S.141
Ligand excluded by PLIPEDO.11: 4 residues within 4Å:- Chain A: M.143
- Chain B: Q.55, S.184, Y.186
Ligand excluded by PLIPEDO.12: 5 residues within 4Å:- Chain B: P.38, W.103, Y.166
- Chain C: R.96, I.123
Ligand excluded by PLIPEDO.14: 9 residues within 4Å:- Chain B: A.109, Y.110, S.111, S.112, M.143
- Chain C: Q.55, V.70, L.119, A.137
Ligand excluded by PLIPEDO.17: 6 residues within 4Å:- Chain B: R.114
- Chain C: D.68, R.114, Q.117, R.139, S.141
Ligand excluded by PLIPEDO.18: 4 residues within 4Å:- Chain B: M.143
- Chain C: Q.55, S.184, Y.186
Ligand excluded by PLIPEDO.19: 5 residues within 4Å:- Chain C: P.38, W.103, Y.166
- Chain D: R.96, I.123
Ligand excluded by PLIPEDO.20: 8 residues within 4Å:- Chain C: A.109, Y.110, S.111, S.112, M.143
- Chain D: Q.55, V.70, L.119
Ligand excluded by PLIPEDO.23: 6 residues within 4Å:- Chain C: R.114
- Chain D: D.68, R.114, Q.117, R.139, S.141
Ligand excluded by PLIPEDO.24: 4 residues within 4Å:- Chain C: M.143
- Chain D: Q.55, S.184, Y.186
Ligand excluded by PLIPEDO.25: 4 residues within 4Å:- Chain D: P.38, W.103, Y.166
- Chain E: I.123
Ligand excluded by PLIPEDO.27: 9 residues within 4Å:- Chain D: A.109, Y.110, S.111, S.112, W.164
- Chain E: Q.55, V.70, L.119, A.137
Ligand excluded by PLIPEDO.28: 9 residues within 4Å:- Chain A: Q.55, V.70, L.119, A.137
- Chain E: A.109, Y.110, S.111, S.112, M.143
Ligand excluded by PLIPEDO.31: 6 residues within 4Å:- Chain D: R.114
- Chain E: D.68, R.114, Q.117, R.139, S.141
Ligand excluded by PLIPEDO.32: 5 residues within 4Å:- Chain D: S.111, M.143
- Chain E: Q.55, S.184, Y.186
Ligand excluded by PLIPEDO.33: 5 residues within 4Å:- Chain A: R.96, T.97, I.123
- Chain E: W.103, Y.166
Ligand excluded by PLIP- 2 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x OXL: OXALATE ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bueno, R.V. et al., Interactions between 2'-fluoro-(carbamoylpyridinyl)deschloroepibatidine analogues and acetylcholine-binding protein inform on potent antagonist activity against nicotinic receptors. Acta Crystallogr.,Sect.D (2022)
- Release Date
- 2020-02-19
- Peptides
- Soluble acetylcholine receptor: ABCDE
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
E
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-pentamer
- Ligands
- 5 x H92: 4-[5-[(1~{R},2~{R},4~{S})-7-azabicyclo[2.2.1]heptan-2-yl]-2-fluoranyl-pyridin-3-yl]benzamide(Non-covalent)
- 5 x PO4: PHOSPHATE ION(Non-functional Binders)
- 20 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 2 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x OXL: OXALATE ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bueno, R.V. et al., Interactions between 2'-fluoro-(carbamoylpyridinyl)deschloroepibatidine analogues and acetylcholine-binding protein inform on potent antagonist activity against nicotinic receptors. Acta Crystallogr.,Sect.D (2022)
- Release Date
- 2020-02-19
- Peptides
- Soluble acetylcholine receptor: ABCDE
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
E